Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 billion in deposits for the shot.
Moderna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of the 30,000 subjects in the trial.
Pfizer said it will wait until after the US election to file its COVID-19 vaccine with the US regulator, as it awaits important safety data to become available.
It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than six people to contain growing numbers of new cases and the lead vaccine trial from AstraZe
Health officials in the US have been told to prepare for a COVID-19 vaccine to be ready by November ahead of the US presidential elections, according to press reports.